Print

TG Therapeutics, Inc. (MHA) Initiates First-In-Human, Phase I Clinical Trial for Its Novel, Highly Specific PI3K-Delta Inhibitor, TGR-1202, in Patients With Hematologic Malignancies  
1/8/2013 9:05:40 AM

NEW YORK, Jan. 8, 2013 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX) today announced that it has initiated a Phase I, open label, multi-center, first-in-human clinical trial of its novel PI3K delta inhibitor, TGR-1202, in patients with hematologic malignancies.
//-->